Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer files suit against J&J over Remicade contracts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/20/2017 | 09:24pm CEST
The Pfizer logo is seen at their world headquarters in New York

(Reuters) - Drugmaker Pfizer Inc (>> Pfizer) on Wednesday filed a lawsuit against Johnson & Johnson (>> Johnson & Johnson), saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

(Reuters) - Drugmaker Pfizer Inc (>> Pfizer) on Wednesday filed a lawsuit against Johnson & Johnson (>> Johnson & Johnson), saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Pfizer said in the suit that J&J is offering discounts on its Remicade treatment in exchange for essentially excluding Pfizer's drug from insurance coverage, keeping it out of the hands of patients.

J&J said in an e-mailed statement that the lawsuit was without merit and that the company is competing on value and price.

"To date Pfizer has failed to demonstrate sufficient value to patients, providers, payers and employers," said Scott White, President of Janssen Biotech Inc, a unit of J&J.

J&J signed exclusionary contracts with health insurers, hospitals and doctor groups after U.S. regulators approved it as a reasonable substitute for Remicade in 2016, Pfizer said.

The contracts with insurers - including UnitedHealth Group (>> UnitedHealth Group), Anthem Inc (>> Anthem Inc), Aetna Inc (>> Aetna Inc) and Cigna Corp (>> CIGNA Corporation) - covered about 70 percent of the commercially insured patients in the United States, the lawsuit said.

Both Aetna and Anthem declined to comment. Other U.S. insurers contacted for this story did not have an immediate comment.

Remicade is an infused treatment for chronic autoimmune disorders and costs about $4,000 per dose, or $26,000 a year, Pfizer said in the suit. Its Inflectra rival is priced 19 percent lower than that list price.

But Pfizer said it has not been able to reach customers because of J&J's anticompetitive actions. The suit comes at a time when insurers, consumers and the U.S. government have pushed for lower drug prices, saying double-digit annual price increases are unsustainable.

Biosimilars are intended to be lower cost alternatives to expensive biotech medicines. But because they are made from living cells and it is not possible to make an exact copy of the branded medicine, they are not automatically substituted for the existing branded drug the way a generic drug would be.

Pfizer said in the lawsuit that J&J's contracts with many insurers exclusively pay for Remicade and only pay for Inflectra in limited cases where patients "fail first" on Remicade.

In return, Pfizer said, J&J pays after-market rebates on both new and existing customers' Remicade purchases. To make up for the J&J rebates and discounts on this large base of old and new customers, Pfizer said it would need to price Inflectra below its own average variable cost.

Pfizer shares were up 1.3 percent, or 45 cents, at $35.90 and J&J shares fell 1.6 percent, or $2.10, to $133.11.

The case was filed in the U.S. District Court for the Eastern District of Pennsylvania.

(Reporting by Caroline Humer in New York and Divya Grover in Bengaluru; editing by Sriraj Kalluvila, Nick Zieminski and G Crosse)

By Caroline Humer

Stocks mentioned in the article
ChangeLast1st jan.
AETNA -0.11% 191.33 Delayed Quote.6.06%
ANTHEM INC 1.06% 248.63 Delayed Quote.10.50%
CIGNA CORPORATION 4.12% 177.75 Delayed Quote.-15.94%
JOHNSON & JOHNSON -1.01% 127.8 Delayed Quote.-7.59%
PFIZER 0.03% 37.66 Delayed Quote.3.95%
UNITEDHEALTH GROUP 2.05% 255.42 Delayed Quote.15.86%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:28pJOHNSON & JOHNSON : Trial Attorneys Willing to Invest Thousands in Upcoming Elec..
AQ
05:55aJOHNSON & JOHNSON : Company news in brief
AQ
07/18JOHNSON & JOHNSON : and picks Penn for research node
AQ
07/18JOHNSON & JOHNSON REPORTS 2018 SECON : 2018 Second-Quarter Sales of $20.8 Billio..
AQ
07/18JOHNSON & JOHNSON : and picks Penn for research-talk hub
AQ
07/18JOHNSON & JOHNSON : Agloan-US Stocks Rebound on Tech, House Goods
AQ
07/18CONFIDANTE OF TAIWAN PRESIDENT TO TA : reports
AQ
07/18JOHNSON & JOHNSON : J&J stops Invokana trial early after success in kidney disea..
AQ
07/18GENMAB : Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 201..
AQ
07/18JOHNSON & JOHNSON : Janssen Announces U.S. FDA Approval of SYMTUZATM (D/C/F/TAF)..
PU
More news
News from SeekingAlpha
03:04aYOUR DAILY PHARMA SCOOP : Tonix Progresses, J&J Succeeds, Quidel Is Cleared 
07/18INTUITIVE SURGICAL : Potentially Attractive Entry Point Following Any Post-2Q18 .. 
07/18Why Johnson & Johnson Is An Attractive Investment 
07/18FDA committed to easing approval path for biosimilars 
07/18Johnson & Johnson 2018 Q2 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 81 273 M
EBIT 2018 24 895 M
Net income 2018 16 036 M
Debt 2018 12 563 M
Yield 2018 2,79%
P/E ratio 2018 18,60
P/E ratio 2019 16,73
EV / Sales 2018 4,42x
EV / Sales 2019 4,16x
Capitalization 346 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 143 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225
AMGEN10.87%128 318